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A B S T R A C T   
The past four decades have seen enormous efforts placed on a search for molecular markers of schizophrenia 
using positron emission tomography (PET) and single photon emission computed tomography (SPECT). In this 
narrative review, we cast a broad net to define and summarize what researchers have learned about schizo-
phrenia from molecular imaging studies. Some PET studies of brain energy metabolism with the glucose 
analogue FDGhave have shown a hypofrontality defect in patients with schizophrenia, but more generally 
indicate a loss of metabolic coherence between different brain regions. An early finding of significantly increased 
striatal trapping of the dopamine synthesis tracer FDOPA has survived a meta-analysis of many replications, but 
the increase is not pathognomonic of the disorder, since one half of patients have entirely normal dopamine 
synthesis capacity. Similarly, competition SPECT studies show greater basal and amphetamine-evoked dopamine 
occupancy at post-synaptic dopamine D2/3 receptors in patients with schizophrenia, but the difference is likewise 
not pathognomonic. We thus propose that molecular imaging studies of brain dopamine indicate neurochemical 
heterogeneity within the diagnostic entity of schizophrenia. Occupancy studies have established the relevant 
target engagement by antipsychotic medications at dopamine D2/3 receptors in living brain. There is evidence for 
elevated frontal cortical dopamine D1 receptors, especially in relation to cognitive deficits in schizophrenia. 
There is a general lack of consistent findings of abnormalities in serotonin markers, but some evidence for 
decreased levels of nicotinic receptors in patients. There are sparse and somewhat inconsistent findings of 
reduced binding of muscarinic, glutamate, and opioid receptors ligands, inconsistent findings of microglial 
activation, and very recently, evidence of globally reduced levels of synaptic proteins in brain of patients. One 
study reports a decline in histone acetylase binding that is confined to the dorsolateral prefrontal cortex. In most 
contexts, the phase of the disease and effects of past or present medication can obscure or confound PET and 
SPECT findings in schizophrenia.   
1. Introduction 
Emil Kraepelin, in his clinical description of a progressive psychiatric 
disorder, popularized the term dementia praecox, which dated back to 
earlier work by Bénédict Augustin Morel and Arnold Pick. With the 
increasing rejection of Kraepelin’s diagnostic dichotomy of dementia 
praecox versus manic-depressive psychosis, Paul Eugen Bleuler intro-
duced the term schizophrenias to denote his clinical description of a 
splitting between the emotional and the intellectual functions of the 
personality, and considered dementia to be a secondary aspect of a 
disorder of unknown physical basis. To this day, clinicians and 
researchers generally concur that the clusters of positive and negative 
symptoms of schizophrenia and associated cognitive deficits are mani-
festations of an organic brain disease. However, a century of research 
has not revealed any pathogen, nor does any single genetic factor carry 
great weight in the incidence of schizophrenia, so the underlying or 
causal neuropathology remains elusive. Following upon early findings of 
ventricular enlargement to pneumoencephalography, there has been a 
huge expenditure of efforts in carrying out structural magnetic reso-
nance imaging (MRI) in schizophrenia patients. Meta-analyses of many 
such studies consistently show ventricular enlargement and cortical 
volume loss, especially in the temporal lobe and its associated structures 
* Corresponding author. 
E-mail address: paul.cumming@insel.ch (P. Cumming).  
Contents lists available at ScienceDirect 
Behavioural Brain Research 
journal homepage: www.elsevier.com/locate/bbr 
https://doi.org/10.1016/j.bbr.2020.113004 
Received 16 September 2020; Received in revised form 22 October 2020; Accepted 31 October 2020   
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
5
6
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Behavioural Brain Research xxx (xxxx) xxx
2
such as hippocampus and amygdala [1,2]. A wide range of MR spec-
troscopy studies has indicated abnormalities in brain glutamatergic 
metabolism, redox balance (NAD+/NADH ratio), and mitochondrial 
metabolism in patients with schizophrenia [3]. While such findings 
certainly suggest that something is amiss with cerebral metabolism of 
patients with schizophrenia, we focus this review on findings from 
molecular imaging studies with positron emission tomography (PET) 
and single photon emission computer tomography (SPET/SPECT) that 
examine specific aspects of metabolism and neurotransmission in 
schizophrenia. Rationalized pharmacological therapy for schizophrenia 
should properly derive from knowledge of its neurochemical pathology, 
as in the case of levodopa treatment of Parkinson’s disease, but, as shall 
be seen, the case is less clear for schizophrenia. 
The objective of the present review is to summarize the results of four 
decades of molecular imaging research in schizophrenia. What then 
have almost two generations of molecular imagining research taught us 
about the pathology of schizophrenia, and how might this growing 
knowledge eventually inform a rational and individualized treatment of 
this dreadful disease? Towards answering these questions, we have 
undertaken a non-systematic literature search in the PubMed database 
with key words SPET/SPECT + schizophrenia (which yielded 654 hits) 
and PET + schizophrenia (which yielded 1277 hits). Passing quickly 
over the 75 SPECT studies of cerebral blood flow in schizophrenia, and 
making a selection of representative neuroenergetics PET studies with 
[18F]fluorodeoxyglucose (FDG), we screened out the remaining litera-
ture on PET and SPECT investigations of specific neurochemical markers 
in patients with schizophrenia. Indeed, the search for a neurochemical 
defect in schizophrenia motivated decades of research into plasma and 
urinary metabolites from patients, long preceding the advent of mo-
lecular brain imaging. Here, the history of the pink spot is a cautionary 
tale. Chromatographic analysis of urine extracts from patients revealed a 
pink spot that was absent from samples from control subjects. This spot 
was tentatively identified as a metabolite of mescaline [4], which 
seemed to fit with ideas about abnormal biogenic monoamine meta-
bolism that were current at the time. However, later work called into 
question the pink spot’s chemical identity and specificity as a marker in 
schizophrenia [5]. After a flurry of research, the pink spot proved to be a 
catecholamine metabolite present in tea, which was commonly drunk to 
excess by in-patients [6]. Improved technology yields new spots, in a 
manner of speaking; a recent FDG-PET case study of cerebral energy 
metabolism showed intense focal activation in the bilateral locus 
coeruleus of a patient with schizophrenia [7]. The authors interpreted 
their finding to reveal metabolic activation of the noradrenaline neurons 
of the locus coeruleus, due to some factor such as stress, opioid with-
draw, or an idiosyncratic specific aspect of that patient’s illness. 
2. Cerebral metabolism 
The topic of FDG-PET is a good point of departure for a critical re-
view of molecular brain imaging in schizophrenia, being one of the first 
tracers used for this purpose. FDG is a structural analogue of natural 
glucose that traces the initial stage of glucose metabolism in living cells. 
Once injected into the circulation, FDG enters the brain by facilitated 
diffusion across the blood-brain barrier, and then returns to circulation 
or is phosphorylated by the enzyme hexokinase in living brain cells, both 
neurons and glia. Whereas natural glucose phosphate would continue 
through the glycolytic pathway to pyruvate, and ultimately enter the 
Krebs cycle, FDG-phosphate proceeds no further along the pathway, as it 
is not a substrate for the isomerase reaction. Consequently, the accu-
mulation over time of FDG-phosphate formed in living cells gives an 
index of the local rate of glucose consumption. This rate is synonymous 
with the total energy consumption of the brain tissue, which is exclu-
sively dependent upon glucose as an energy substrate, except for 
example under ketogenic conditions. 
Given the above consideration, maps of cerebral glucose metabolism 
from FDG PET studies should potentially reveal metabolic abnormalities 
in the brain of patients with schizophrenia. Indeed, an early study tested 
just this hypothesis, showing a reduction in the relative FDG uptake in 
medial prefrontal cortex of unmedicated patients [8]. Notably, the in-
dividual uptake in frontal cortex of the patients did not show the usual 
correlation with performance of an auditory discrimination task that is 
evident in healthy volunteers. Here, the implication is that regional 
glucose metabolism is perturbed, having lost its normal associations 
with performance of specific tasks. The findings of hypofrontality to 
FDG-PET concurred with the frequent observations of lower cerebral 
perfusion in frontal cortex first seen in xenon-133 inhalation SPECT 
studies, although with the caveat that hypoperfusion tends to be 
discovered only while patients perform a cognitive task engaging their 
frontal cortex [9]. However, a meta-analysis of many studies of perfu-
sion and metabolism showed an overall pattern of hypofrontality not 
just during task performance, but also during rest, whatever may 
constitute rest when one is lying in a scanner [10]. The distinction is 
important; if hypofrontality were only present due to failure to engage in 
a cognitive task, this would qualify as a state defect, but the occurrence 
of reduced frontal perfusion and metabolism at rest indicates a trait 
defect in schizophrenia. 
The metabolic disturbances of schizophrenia might emerge from a 
failure of normal functional connectivity of different brain regions, i.e. 
thalamo-cortico-striatal circuits, which could manifest in impaired or 
perhaps errant metabolic coupling between different regions of these 
circuits. Indeed, a very early test in a group of patients with schizo-
phrenia of the correlational mapping approach showed a near absence of 
the normal pattern of metabolic coupling under a condition of stimu-
lation with mild electrical shocks [11]. A more recent inter-regional 
correlation analysis of FDG in a group of never-medicated patients 
with schizophrenia showed weaker positive correlations between the 
frontal lobe with other brain regions in the patient group [12]. In a 
group of 70 medication-free patients, FDG uptake in frontal cortex and 
thalamus had a negative correlation with total scores in the BPRS, and 
both with positive and negative subscores [13]. Furthermore, that study 
showed lower right > left metabolic asymmetry in the patients 
compared to a group of 30 healthy controls. In a relatively small group of 
patients, the negative symptomology subscores correlated inversely 
with FDG uptake, which tended to be especially low in structures of the 
right hemisphere [14]. This observation harkens back to thoughts about 
cerebral asymmetry in schizophrenia, derived from Pierre Flor-Henry’s 
observation of an association between schizophreniform psychoses and 
left temporal lobe epilepsy [15]. Post mortem neurochemical analyses 
have given some fragmentary evidence for neurochemical asymmetry, i. 
e. higher dopamine levels in the left amygdala of patients with schizo-
phrenia [16]. We shall return to this theme in the review of dopamine 
PET below. 
While the left hemisphere is normally dominant with respect of 
language function, the hemodynamic response during performance of a 
motor planning task is transiently greater in the right hemisphere of 
healthy volunteers [17]. However, a task dependent activation favoring 
the right side was absent in a group of schizophrenia patients monitored 
by near infrared spectroscopy [18]. An FDG-PET study performed during 
a continuous performance task showed higher factor scores for the left 
temporal lobe in schizophrenia patients in normal controls, where the 
factor score refers to the weighting of some region towards accounting 
for the total variance in the measurement [19]. One might suppose that 
the right hemisphere of schizophrenia patients “stands down” in the face 
of an attentional task, presumably yielding this function to the left 
hemisphere. 
Higher resolution PET instrumentation enables the investigation of 
metabolism in smaller anatomic divisions. Thus, a well-powered FDG- 
PET study in unmedicated schizophrenia patients showed metabolic 
disturbances in divisions of the thalamus, and reported their clinical 
correlates [20]. Lower relative metabolism in the pulvinar nucleus had 
an association with positive symptoms and hallucinations, whereas 
lower metabolism in the mediodorsal thalamus had an association with 
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negative symptoms. Notably, the pulvinar’s role in mediating reciprocal 
connections between parietal association cortex and occipital cortex 
may be consistent with an involvement in positive symptoms. The 
mediodorsal thalamus has reciprocal connectivity with the prefrontal 
and anterior cingulate cortex and the amydala, and receives input from 
the basal ganglia, and is functionally involved in cognition and learning 
[21], which may suggest an involvement in negative symptoms of 
schizophrenia. 
3. Presynaptic dopamine markers 
Molecular imaging research in schizophrenia placed early emphasis 
on examinations of brain dopamine. This was due to the long-standing 
prevalence of a dopamine model of schizophrenia, positing that some 
disease symptoms are due to a functional excess of brain dopamine. 
However, the fortuitous availability of effective dopamine tracers at an 
early stage of molecular imaging research also encouraged that research 
focus. One of the first such radiopharmaceuticals was the dopamine 
synthesis tracer 6-[18F]fluoro-L-DOPA (FDOPA), which accumulates in 
the basal ganglia in PET studies of healthy volunteers, but not in patients 
with nigrostriatal degeneration due to acquired parkinsonism [22]. The 
common carrier for large neutral amino acids reversibly transfers 
circulating FDOPA across the blood brain barrier. Once in brain, FDOPA 
is a substrate for the enzyme DOPA decarboxylase, found most abun-
dantly in striatal terminals arising from the midbrain dopamine neurons, 
where the enzymatic product [18F]fluorodopamine is retained for a time 
within synaptic vesicles. As such, the kinetic model for describing 
FDOPA kinetics follows closely that described above for FDG, but with 
the complication that FDOPA also yields a radioactive brain-penetrating 
metabolite, O-methyl-FDOPA [23]. This must somehow be subtracted 
from the brain signal if one is to isolate the progressive and specific 
labeling of dopamine neurons in living brain [24]. The metabolic trap-
ping of [18F]fluorodopamine in living brain is imperfect due to its 
deamination to acidic metabolites, which are free to diffuse from brain, 
thus leading to progressive loss of specific signal [25]. However, the 
signal loss is of small magnitude during PET recordings of duration less 
than 60 min, such that applying an irreversible trapping model results in 
little bias in the estimation of FDOPA trapping [26]. 
Applying just such an irreversible binding model (analogous to FDG- 
PET), the first PET study of presynaptic dopamine synthesis in unmed-
icated patients with schizophrenia revealed significantly higher striatal 
trapping compared to that in healthy controls [27]. The same study also 
reported increased FDOPA uptake in a small group of epilepsy patients 
with interictal psychosis, suggesting a common dopaminergic compo-
nent in the two forms of psychosis. This result seemed so important to 
the construct of a dopaminergic abnormality in schizophrenia that there 
were numerous replications using FDOPA and other amino acid-based 
PET tracers for dopamine synthesis capacity. A meta-analysis 
compiling such results in hundreds of patients and controls showed 
unambiguously that dopamine synthesis capacity is elevated in patients 
with schizophrenia (Effect size 0.79, p < 0.001) [28]. Indeed, increased 
dopamine synthesis capacity remains one of the best-attested molecular 
imaging findings in schizophrenia. The human basal ganglia does not 
operate in isolation, but is tightly coupled to functioning of the cerebral 
cortex. Thus, it is notable that the increased FDOPA utilization reported 
in a small group of patients with schizophrenia correlated inversely with 
the perfusion increase in prefrontal cortex during performance of an 
executive function task [29]. In effect, the elevated capacity for dopa-
mine signaling in the basal ganglia seemed to link with disabling or 
blocking of a cognitive function mediated by the frontal cortex. How-
ever, we emphasize that elevated dopamine synthesis capacity is not a 
pathognomonic sign of schizophrenia, since about half of unmedicated 
patients have entirely normal FDOPA PET findings. Furthermore, a 
recent study in unmedicated schizophrenia patients did not show any 
elevation in striatal dopamine synthesis capacity, perhaps reflecting 
aspects of reference tissue methods for quantitation [30]. Nonetheless, 
that study revealed anatomically distinct associations between FDOPA 
trapping with reward prediction error signaling to fMRI; unmedicated 
patients failed to show the normal positive association between dopa-
mine synthesis capacity in limbic striatum with reward prediction error 
signaling, although FDOPA uptake in associative striatum did correlate 
with higher scores for positive symptoms. 
Less well attested is our report of two-fold increased turnover of the 
[18F]fluorodopamine formed in brain of a group of schizophrenia pa-
tients, which we detected by applying an extended compartmental 
model to prolonged dynamic FDOPA recordings. We interpreted this 
result to indicate that brain dopamine is “churning” in schizophrenia, 
with the enhanced dopamine breakdown resulting in a paradoxical state 
of “poverty in the midst of plenty” [31]. In such a scenario, dopamine 
signaling might be impaired despite a superabundance of newly syn-
thesized dopamine. Indeed, something similar occurs among healthy 
volunteers treated with a low dose of an antipsychotic medication, 
which acutely results in disinhibition of dopamine synthesis via autor-
eceptor blockade, as revealed by increased FDOPA trapping in striatum 
[32]. Paradoxically, we saw reduced FDOPA trapping in schizophrenia 
patients treated sub-chronically with antipsychotic medication [33]. We 
interpreted this result to be a molecular imaging marker of “depolari-
zation block”, an electrophysiological phenomenon when dopamine 
neurons fall silent in rats that are treated with antipsychotic medication 
for several weeks [34]. A more recent report seemingly recapitulates our 
result, showing relatively reduced FDOPA uptake in patients under 
stable antipsychotic treatment [35], which we argued was a late 
consequence of prolonged autoreceptor blockade [36]. On the other 
hand, a new PET study from London failed to show any significant effect 
of antipsychotic treatment for five weeks on striatal FDOPA utilization 
in first episode patients [37]. Both studies used roughly similar methods 
for FDOPA quantitation (linear graphical analysis relative to a reference 
region), so the disparate results may be a matter of differences in the 
phase of illness between patient groups, or other factors [38]. 
There is general concordance in the literature that there is increased 
dopamine synthesis capacity in populations of unmedicated patients 
with schizophrenia. A PET study in individuals at ultra-high risk (UHR) 
for developing schizophrenia showed elevated striatal FDOPA trapping 
specifically in those patients destined to undergo transition to psychosis 
[39]. Replication in a second cohort also showed increased FDOPA 
utilization in UHR individuals [40], and in another study involving 47 
UHR cases, retrospective reporting of having experienced childhood 
adversity (a significant stressor) was associated with higher FDOPA 
uptake [41]. In addition, there was increased FDOPA uptake in healthy 
first-degree relatives (siblings and children) of patients with schizo-
phrenia [42]. While of moderate effect sizes, scatter plots of data from 
these studies all showed significant overlap in results between patients 
and controls, as is usually the case in the schizophrenia literature. As 
noted above, a pre-existing difference in the dopamine system revealed 
by FDOPA PET is not a pathognomonic sign of schizophrenia, since half 
of patients have normal FDOPA results. Something is clearly amiss with 
the dopamine system in patients at a group level, but FDOPA PET does 
not itself offer reliable confirmatory diagnosis on an individual basis. On 
the other hand, an FDOPA study of groups of treatment-resistant pa-
tients and responders showed elevated FDOPA uptake while on medi-
cation, especially among the responders [43]. The magnitude of the 
difference was large, and the authors interpreted their findings as evi-
dence that high/excessive dopamine synthesis capacity was a precon-
dition for good response to antipsychotic treatment. In a continuation of 
that investigation, the authors reported that non-responders to first line 
treatment showed lower FDOPA uptake when under treatment with the 
“second-generation” antipsychotic (SGA) medications clozapine or ris-
peridone [44]. However, since the scans were all recorded while the 
patients were under treatment with an antipsychotic medication, a 
contrary interpretation seems possible, i.e. only those responding with a 
downregulation of dopamine synthesis capacity upon first-line treat-
ment enjoyed full clinical benefits, while those with a refractory 
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dopamine system had a lesser therapeutic response. A study of longi-
tudinal design with follow-up scanning might distinguish whether low 
FDOPA uptake in the second-line treatment group was an underlying 
trait, or a response to SGA medication. Recently, machine-learning 
techniques applied to baseline FDOPA PET scans in unmedicated pa-
tients proved fit to predict their response to first-line antipsychotic 
treatment with a receiver operating curve area under the curve 
approaching 0.90 [45]. As such, that may be the first molecular imaging 
study specifically designed to inform treatment decisions in patients 
with schizophrenia. 
Retention of FDOPA-derived PET signal in nigrostriatal nerve fibres 
requires its enzymatic transformation to [18F]fluorodopamine, which is 
stored in synaptic vesicles via the vesicular monoamine transporter 
(VMAT), or is released as a false neurotransmitter. [18F]Fluorodop-
amine, like endogenous dopamine, is a substrate for dopamine trans-
porters (DAT) in the plasma membrane, which can transfer it along with 
dopamine back into the presynaptic terminal. Thus, VMAT and DAT 
present alternate targets for molecular imaging studies of the dopamine 
system. There does not seem to have been any PET study of VMAT in 
patients with schizophrenia. A PET study with the DAT ligand [11C]PE2I 
found elevated binding potential (BPND, the specific binding relative to a 
reference region) in the putamen, midbrain, and thalamus in a group of 
21 patients with chronic schizophrenia, and showed that individual 
results correlated with certain clinical symptoms [46]. However, 
meta-analysis of 16 PET and SPECT studies comprising groups of nearly 
300 patients and controls did not detect any significant difference in 
DAT availability [47]. The variance of the DAT endpoints was signifi-
cantly higher in the patient group, thus hinting at heterogeneity of DAT 
expression, which might reflect effects of previous treatment. 
Multi-tracer PET studies in non-human primate show that DAT expres-
sion has a much higher age-dependence than is typically seen for FDOPA 
or VMAT [48], suggesting a greater degree of plasticity for DAT. Rather 
than being simply a passive actor in synaptic transmission, the activity of 
DAT is a moderator of antipsychotic efficacy; preclinical research has 
shown that individual rats with upregulated DAT expression in the 
course of chronic antipsychotic treatment acquire resistance to the 
behavioral effects of the medication [49,50]. On the other hand, 
downregulation of DAT activity due to normal aging or in the context of 
psychostimulant abuse disables dopamine re-uptake from the extracel-
lular space and reduces the efficacy of antipsychotic medication [49,50]. 
Thus, we suppose that treatment effects, age, and trait heterogeneity all 
may influence the results of DAT molecular imaging studies in 
schizophrenia. 
4. Post-synaptic dopamine markers 
While FDOPA PET and DAT studies give indices of the biochemical 
integrity of presynaptic dopamine terminals, the dopamine-responsive 
elements in brain mainly reside on post-synaptic membranes, i.e. on 
the medium spiny neurons of the striatum. The dopamine receptors are 
typical G-protein coupled receptors belonging to two broad pharmaco-
logical classes, namely. the D1-like and D2-like receptors. Molecular 
imaging studies have long placed main emphasis on the dopamine D2- 
like receptors, given the antipsychotic properties of many D2-antago-
nists. The very first such studies of schizophrenia used the butyrophe-
none ligand [11C]NSMP, despite its lack of absolute pharmacological 
specificity for dopamine receptors and despite its languid kinetics in 
vivo, which present problems for quantitative analysis. Although its 
equilibrium binding to D2-like receptors (the composite of D2, D3, and 
the sparse D4 subtypes) occurs very late in the scan, the initial uptake 
into brain follows an irreversible binding model. Applying this model to 
data recorded during the first 60 min after injection, the pioneering 
study of its type indicated two-fold elevated rate constant (k3; min− 1) for 
the association of [11C]NSMP to its binding sites in the caudate-putamen 
of drug naïve patients with schizophrenia [51]. That study was even-
tually followed by an attempt at replication, which showed no group 
difference in striatal [11C]NSMP binding between never-medicated pa-
tients and healthy volunteers [52]. 
This discrepancy might have been due to the somewhat problematic 
quantitation of [11C]NSMP binding. Thus, there was a need for a 
reversibly binding D2-like ligand for molecular imaging studies, a need 
that was eventually met by the benzamide D2/3 antagonist [11C] 
raclopride for PET studies and by its chemical congener [123I]IBZM for 
scintigraphy and SPECT imaging. The benzamide class of molecules has 
nearly complete pharmacological specificity for dopamine D2/3 re-
ceptors, unlike the butyrophenones, which also bind to dopamine D4 and 
serotonin 5HT2A receptors. [11C]Raclopride also has rapid kinetics, 
approaching equilibrium binding in brain within less than an hour, 
which facilitates quantitation of its binding potential (BPND) relative to 
uptake in a non-binding region such as cerebellum. 
The BPND for a receptor ligand of high molar activity is proportional 
to the ratio of the saturation binding parameters, Bmax/KD, in living 
brain. However, if the injected mass is so high that there is substantial 
(>5%) occupancy at the binding sites, then the measured BPND declines 
in proportion to that occupancy. Further, if the experimenter measures 
BPND twice in the same individual, once with tracer of high molar ac-
tivity, and again with high injected mass, it becomes possible to separate 
the parameters Bmax and KD, by making a “two-point” Scatchard anal-
ysis. This rather onerous experimental design has been successfully 
applied in a [11C]raclopride PET study of 20 healthy volunteers and 20 
unmedicated patients with schizophrenia [53], which showed no group 
difference either in Bmax or KD. In this approach, the Bmax estimate 
should be isolated from effects of competition from endogenous dopa-
mine, but the prevailing dopamine concentration in vivo can alter the 
apparent KD. That neither parameter should differ between groups, 
would thus argue against important differences in D2/3 receptor occu-
pancy by endogenous dopamine, although experiments described below 
indicate elevated dopamine binding in patients with schizophrenia. 
The various discrepancies in early investigations of striatal dopamine 
D2-like receptor availability in schizophrenia raised a controversy that 
eventually yielded to a meta-analysis of many PET studies, as well as 
SPECT studies with the benzamide antagonist ligand [123]IBZM. A meta- 
analysis focusing on studies of extrastriatal D2/3 receptors showed small 
reductions in cortex and thalamus of patients, but this effect did not 
reach significance and had a confound due to medication history [54]. 
Compilation of the available molecular imaging studies targeting stria-
tum indicated slightly elevated dopamine D2/3 receptor availability 
among patients, which was partially attributable to results in older pa-
tients, and to studies using butyrophenone ligands [55]. On the other 
hand, a later meta-analysis of 22 PET/SPECT studies showed higher 
striatal binding with a summary effect size of 0.26, again potentially 
confounded by previous antipsychotic treatment [28]. Thus, the initial 
[11C]NMSP PET finding of greatly elevated striatal D2-receptor avail-
ability subsequently regressed to the mean in the compilation of many 
results, leaving a real effect, albeit of small magnitude. Interestingly, a 
very recent meta-analysis showed elevated variability of striatal D2/3 
receptor results (and likewise for DAT in the presynaptic terminals) of 
patients compared to healthy controls [47]. This suggests the presence 
of heterogeneous baseline dopamine D2/3 receptor changes in patients, 
despite their shared diagnosis of schizophrenia. Such a phenomenon 
calls for studies of patient sample size sufficient to accommodate the 
biological variance and to support factor analysis, which might parse out 
disease subtypes in relation to specific symptom clusters, while cor-
recting for effects of previous treatment with antipsychotic medication. 
Unstated in the above account is the effect of competition from 
endogenous dopamine on the availability of dopamine D2/3 sites in 
living brain. This is a well-established phenomenon for benzamide 
antagonist ligands and for certain agonists e.g. [56], but not for buty-
rophenones [57], such that amphetamine-evoked dopamine release in-
creases the competition against the binding of many commonly used 
PET/SPECT ligands. Amphetamine challenge releases intraneuronal 
dopamine through a mechanism of facilitated exchange/diffusion. After 
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administration of a low dose of amphetamine, binding of the benzamide 
SPECT ligand [123I]IBZM rapidly declined by about 20 % in unmediated 
schizophrenia patients, whereas the same treatment evoked only a 7 % 
decline in healthy controls [58], a finding which was replicated in a 
second cohort, albeit with slightly less group difference [59]. The 
greater variance of delta-BPND results in patients is again indicative of 
disease heterogeneity, and indeed, other research has shown a depen-
dence of the amphetamine effect on the phase of illness, with greater 
dopamine release occurring in a state of worsening symptoms than 
during remission [38]. Partialling out the effect of symptom severity 
might help to discern the inherent magnitude of this relationship within 
a population. 
Psychosocial stress evoked an elevated striatal dopamine release as 
measured by PET examination with the D3-prefering agonist [11C]PHNO 
in a group of (n = 25) immigrants with high risk for schizophrenia, as 
compared to a native-born control group [60]. In fact, the stress evoked 
a 3 % reduction in D2/3 availability in the control group, versus a 3% 
increase in the at-risk group, as compared to 15 % reduction in patients 
with schizophrenia. This stands somewhat in contrast to an earlier [11C] 
raclopride PET study in schizotypal individuals [61], who are at high 
risk for developing psychosis. Here, the psychosocial stress evoked an 
apparent dopamine release only in the subgroup of schizotypal in-
dividuals with anhedonia, i.e. negative as distinct from positive schiz-
otypy. This discrepancy might reflect the greater sensitivity of [11C] 
PHNO binding (an agonist) to competition from endogenous dopamine, 
or might have more relation to neurochemical heterogeneity within the 
populations. 
Hyper-responsivity of dopamine release to amphetamine challenge 
would most likely be a property of the presynaptic dopamine terminals. 
Behavioral sensitization to effects of amphetamine is a well-established 
phenomenon in experimental animals, and certainly has a presynaptic 
component. Furthermore, longitudinal [11C]raclopride PET studies in 
healthy volunteers show a potentiation of the binding change after only 
a few repeated exposures to amphetamine as much as a year previously 
[62]. We have recently shown that mildly sensitizing amphetamine 
treatment potentiates the binding reduction of the D3-prefering agonist 
ligand [11C]PHNO binding evoked by amphetamine challenge in 
healthy controls, attaining a magnitude similar to that seen in 
un-sensitized patients with schizophrenia [63]. The parsimonious 
interpretation here is that repeated exposure to amphetamine induces a 
plastic change in the presynaptic terminals of healthy volunteers, thus 
enhancing the magnitude of the dopamine release evoked by a subse-
quent challenge. In this scenario, patients with schizophrenia are in a 
natural or pre-existing state of sensitization. 
However, sensitization to effects of psychostimulants might also 
have a post-synaptic component, if the dopamine receptors are more 
abundant or show enhanced coupling to their signal transduction 
pathways. This latter scenario might occur if the post-synaptic receptors 
were in a high affinity state for binding dopamine and other agonists. 
Testing this hypothesis in a PET study using the D3-prefering agonist 
ligand [11C]PHNO failed to show any difference in binding between 
patient and healthy control groups [64]. Furthermore, there was no 
difference in the amphetamine-evoked reduction in the striatal binding 
of the D2/3 agonist ligand [11C]NPA in groups of (n = 14) unmedicated 
patients and healthy controls, nor did the individual binding reductions 
in the patient group correlate with worsening of positive symptoms 
[65]. 
Increasing the interstitial dopamine levels through psychostimulant 
drug treatment or by performing certain cognitive tasking imparts 
greater competition against the binding of [11C]raclopride and certain 
other tracers relative to the tonic dopamine competition prevailing at a 
baseline condition. The converse pharmacological challenge, to cause 
depletion of dopamine levels, can unmask this basal occupancy. While 
reserpine serves admirably for dopamine depletion in rodent studies 
[56], it can produce an excessive dopamine depletion, exceeding the 
safety margin for research studies in human volunteers. However, 
partial inhibition of dopamine synthesis with α-methyl-para-tyrosine 
(AMPT) is a well-tolerated pharmacological approach for transiently 
inducing dopamine depletion in human volunteers. The striatal binding 
of [123I]IBZM at striatal D2/3 receptors thus increases after AMPT 
treatment in proportion to the basal occupancy by dopamine. The 
magnitude of this increase was higher in a group of patients with 
schizophrenia than in healthy controls, thus revealing their elevated 
basal occupancy by dopamine [66]. However, the binding change was 
highly variable between patients, and showed a strong inverse rela-
tionship with the extent of dysphoria experienced in individuals due to 
the dopamine depletion [67]. Thus, low basal occupancy is a predictor 
for greater dysphoria experienced upon dopamine depletion, which may 
be relevant to the generally poor compliance of dysphoric patients 
treated with antipsychotic medication. Furthermore, anti-dopaminergic 
compounds may have less therapeutic effect in those experiencing 
dysphoria simply because they already have relatively low dopamine 
signaling. Basal occupancy findings are highly variable, both in healthy 
controls and in patients; meta-analysis of results in controls showed 
occupancy in the range of 8–21 %, with a weighted average of 11 % 
[68]. While this may reflect biological variability or the range of re-
sponses in a stressful environment, there are also methodological con-
siderations at play. In particular, the individual pharmacodynamic 
response to oral AMPT treatment will depend on time of fasting and the 
total plasma concentration of large neutral amino acids at the time of 
molecular imaging. 
Dynamic changes in receptor availability are not just a matter of 
competition from endogenous dopamine, but also involve agonist- 
induced internalization of receptors, such that they become inacces-
sible to benzamide ligands. The agonist can be dopamine itself, or 
agonist drugs such as quinpirole. In a [11C]raclopride PET study in non- 
human primates, escalating doses of the agonist quinpirole promoted 
the internalization of D2/3 receptors, as shown by declining striatal 
BPND. Meanwhile, concomitant fMRI recordings showed a steady decline 
of the effect of quinpirole on neurovascular coupling, consistent with 
loss of externalized and functional receptors [69]. In a human study with 
repeated PET scanning, a single challenge with amphetamine reduced 
striatal [11C]raclopride binding relative to baseline by 12 % at three 
hours, 10 % at six hours and 6 % at nine hours in healthy controls [70]. 
Thus, the receptor availability changes outlasted the psychostimulant 
effects of the drug, no doubt reflecting a receptor internalization pro-
cess. Patients with schizophrenia in that study showed a trend towards 
potentiation and prolongation of the internalization effect, which might 
indicate a defect in receptor cycling. However, the variance in the 
binding changes was considerably higher in the patients, again raising 
the possibility of neurochemical heterogeneity within a single diagnostic 
entity. Indeed, there emerges from the molecular imaging literature a 
consistent picture of heterogeneity of schizophrenia with respect to the 
presence or absence of functional hyperdopaminergia. This issue has 
great bearing on the approximately 30 % of patients with schizophrenia 
patients who have poor therapeutic response to antipsychotic medica-
tion [71]. 
Dopamine D1 receptors are nearly as abundant in striatum as are D2/3 
receptors [72], and greatly predominate over D2-like receptors in cere-
bral cortex, where they are linked to cognitive function. However, there 
is scant documentation of the status of D1 sites in schizophrenia. One 
study with the partially selective D1 antagonist ligand [11C]SCH23390 
showed no difference in striatal binding, but 13 % lower binding in 
dorsolateral prefrontal cortex (DLPFC) of a group of 18 never-medicated 
patients compared with 17 controls [73]. The authors’ summary of the 
seven published D1 PET studies showed that one investigation reported 
20 % lower [11C]SCH23390 binding in striatum of patients with 
schizophrenia compared to their unaffected twins, and similar re-
ductions in widespread cortical regions [74]. However, these differences 
seemed to bear some relationship with the medication history of the 
patients. 
A study comparing two D1 ligands ([11C]SCH23390 and [11C] 
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NNC112) in the same patient and control groups showed 33 % lower D1 
availability in frontal, anterior cingulate and temporal cortex of the 
patients, and 20 % lower binding in striatum [75]. A similar study of the 
two ligands showed globally 5–10 % higher BPND in a small group of 
drug free or naïve patients with schizophrenia [76], thus in contrast to 
preclinical findings that the two ligands differed with respect to their 
behavior in vivo [77]. Other research comparing drug naïve and previ-
ously treated patients with schizophrenia showed 33 % higher [11C] 
NNC112 BPND in DLPFC specifically in the drug-naïve patient group 
[78]. The higher D1-receptor availability in DLPFC of drug-free and 
-naive patients correlated with poor performance of the n-back test of 
working memory [79], whereas there was no such relationship in 
healthy volunteers [80]. Findings with hybrid PET/fMRI imaging 
showed that cortical dopamine signaling via D1-receptors supports 
intracortical cross talk that engages cognitive resources in the perfor-
mance of working memory [81]. In relation to cognitive function, there 
is a distinction between sensitivity of dopamine D1-receptors and their 
absolute abundance [82]. Thus, D1-receptor findings in schizophrenia 
are especially difficult to interpret, as ordinary PET methods do not 
separate availability/abundance of the receptors from their sensitivity, 
both of which may be abnormal. 
5. Assessment of antipsychotic target engagement 
The application of molecular imaging that has had the largest impact 
on clinical practice in psychiatry is the determination of occupancy of 
D2-like dopamine receptors by antipsychotic drugs. Although the phar-
maceutical industry has been trying to develop a non-dopaminergic 
antipsychotic compound for decades, all clinically used drugs for the 
treatment of schizophrenia are still either antagonists or partial agonists 
at D2/3 receptors. The assessment of D2/3 receptor occupancy allows the 
determination of the clinically useful drug dose, and it is now a routine 
tool for drug development [83]. Molecular imaging helps in establishing 
the relationship between plasma levels of the respective drug and the 
proportion of target molecules occupied in brain over time [84]. 
Monitoring of clinical effects and adverse reactions as a function of oc-
cupancy provides important information about relationships between 
brain and plasma drug levels and dosage regimens, but gives also in-
sights into mechanisms of drug action. 
PET/SPECT occupancy studies based on the principle that the 
experimental pharmaceutical displaces the radiotracer, which itself 
binds to the target molecule at tracer concentrations, thus avoiding mass 
effects. The extent of this displacement relates to the baseline binding of 
the radiotracer in unblocked state. Consequently, the radioactivity in the 
target region in the blocked vs. the unblocked state provides the target 
occupancy (in %) as follows [84]:  
Occupancy [%] = 100 – [(Tracer Bindingblocked/ Tracer Bindingunblocked) ×
100]                                                                                                    
Because it is often not feasible to study patients with schizophrenia in 
medication-free state, the PET/SPECT examinations often reflect the 
pharmacologically blocked state only. Unblocked baseline data from 
healthy volunteers must then serve for calculating the occupancy, 
assuming that patients and controls differ only marginally with respect 
to D2/3 receptor availability at baseline, an issue discussed in some detail 
above. Fig. 1 depicts occupancy at cerebral dopamine receptors as a 
function of the plasma concentrations of antipsychotic medications. 
The earliest PET occupancy studies conducted in the late 1980s 
suggested that clinically effective doses of first-generation antipsy-
chotics such as haloperidol occupy D2-like dopamine receptors in the 
human striatum in the range between 65 and 90 % [85]. A “therapeutic 
window” between 65 and 80 % striatal occupancy is now widely 
accepted for antipsychotic drug action, including most of the 
second-generation antipsychotics (SGAs) [86]. Rersults suggest a "ceil-
ing" of about 65 % occupancy of striatal dopamine D2/3 receptors for 
sufficient treatment response, although such a high occupancy does not 
necessarily mean that every patient sufficiently improves. Upon raising 
antipsychotic doses to provoke greater than 80 % occupancy at brain 
receptors, the risk for extrapyramidal side effects (EPS, an iatrogenic 
parkinsonian syndrome) increases substantially. There are certain ex-
ceptions to those general rules [87]. Thus, clozapine and quetiapine 
both bind with such low affinity to D2-like dopamine receptors that even 
at high plasma concentrations they practically never occupy striatal D2/3 
receptors to an extent that is associated with EPS [88]. 
Partial D2/3 agonists, on the other hand, almost completely occupy 
D2/3 receptors at clinically effective doses [89]. There is unequivocal 
evidence for nearly complete therapeutic occupancy for all three clini-
cally available partial agonists, i.e. aripiprazole [90], brexpiprazole 
[91], and cariprazine [92]. Presumably, the full occupancy by partial 
agonists “clamps” dopaminergic signaling at some level sufficient to 
avoid EPS, while avoiding the excessive signaling perhaps occurring in 
patients with schizophrenia. In the converse condition, treatment of 
Parkinson’s disease with pramipexole (a full agonist) alleviates motor 
symptoms while obtaining only a very low occupancy in the basal 
ganglia [93]. 
The utility of occupancy studies in schizophrenia is by no means 
limited to applications for the dopamine system. Early on, researchers 
Fig. 1. Characteristic binding curves of antipsychotic drugs in 
human striatum as measured with PET. Dashed lines represent 
the 80 % threshold occupancy values for extrapyramidal 
symptoms (EPS) and the 65 % threshold for obtaining anti-
psychotic effects. The green line, showing that they fall within 
the 65-80 % “therapeutic window” of occupancy and thera-
peutic plasma concentrations, characterizes most antipsy-
chotics, including most of the SGAs. The red line indicates 
occupancy by antipsychotics with low affinity for D2/D3 re-
ceptors. Even at high plasma concentrations, occupancies 
usually do not cross the 80 % threshold for extrapyramdical 
side effects (EPS). Such compounds exert antipsychotic effects 
despite their relatively low occupancy in the striatum. The blue 
binding curve is typical for all clinically available partial 
agonist antipsychotic medications; such medications have 
antipsychotic effects often at almost total saturation of D2/3 
receptors (in the flat part of the curve), as represented by the 
blue area. Presumably, complete occupancy by a partial 
agonist “clamps” the receptor activation at some level falling 
below the signaling by endogenous dopamine in the untreated 
condition.   
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exploited the ambivalent specificity of [11C]NMSP (D2-like receptors in 
striatum versus serotonin 5-HT2A receptors in cortex) to show that ris-
peridone established roughly similar occupancy at both binding sites 
[94]. In recent elaboration of that approach, the occupancies by brex-
ipiprazole at dopamine D2/3 and serotonin 5HT1A and 5HT2A receptors 
and at serotonin transporters was investigated in a multitracer PET study 
[91]. SPECT studies with the muscarinic acetylcholine receptor ligand 
[123I]-IDEX revealed 50 % occupancy by the SGA olanzapine, versus 
only 25 % occupancy by risperidone [95]. In general, the demonstration 
of off-target (non-dopaminergic) binding of an antipsychotic medication 
may be relevant to understanding its side-effect profile. Alternately, 
occupancy studies may establish engagement of a medication at new 
molecular targets, for example in an occupancy study of the potentially 
therapeutic drug tropisetron at α7 nicotinic receptors labelled with [11C] 
CHIBA-1001 [96]. 
6. Brain serotonin markers 
Post mortem neurochemical analysis in a small group of patients 
dying with schizophrenia suggested lower dopamine content and 
elevated serotonin metabolite levels in sporadic cases with paranoia, 
and higher levels of dopamine in a familial – formerly called hebe-
phrenic – type schizophrenia [97]. While dopamine tissue content may 
bear little relationship with the dynamic aspect of dopamine measured 
by molecular imaging, the elevated serotonin finding might imply 
elevated turnover of that neurotransmitter. There have been no PET 
studies of serotonin synthesis in schizophrenia, although α-[11C]meth-
yl-L-tryptophan might serve for that purpose, at least in the dorsal raphé 
and thalamus, where the specific signal is highest [98]. 
The SPECT ligand [123I]β-CIT binds ambivalently to DAT and sero-
tonin transporters (SERT); due to their differing anatomic distributions, 
the signal in mesencephalon is attributable mainly to SERT, whereas the 
striatal signal mostly reflects DAT. A contrast of [123I]β-CIT binding in 
24 patients with schizophrenia and 22 healthy controls did not reveal 
any group difference in either transporter, despite the earlier demon-
stration of increased amphetamine-induced dopamine release in the 
same patients [99]. The PET ligand [11C]DASB has largely supplanted 
the earlier SERT tracers, due to its selectivity and more sensitive 
depiction of the integrity of serotonin innervations. A [11C]DASB study 
in ten schizophrenia patients and controls did not detect any group 
differences in SERT availability [100]. Another such study using high 
resolution PET to focus on SERT availability in the thalamus likewise 
revealed no group differences between schizophrenia patients con-
trasted with control subjects [101]. However, in the patient group there 
was a negative correlation between the severity of negative symptoms 
with SERT availability in the left anterior thalamic nucleus, which is a 
component of the Papez circuit for establishing declarative memory. 
Another [11C]DASB study showed no difference in SERT availability 
between a group of 19 presently unmedicated patients with schizo-
phrenia contrasted with healthy controls [102]. FDG-PET in the same 
patients showed a typical pattern of cortical hypometabolism; interest-
ingly, the control group manifested significant positive correlations 
between regional SERT in several high binding regions (thalamus, 
extended striatum) with FDG uptake in the same subcortical regions and 
a few cortical regions, and likewise between SERT in some cortical re-
gions with cortical FDG uptake. The corresponding correlation matrices 
for the patients were very sparse. Thus, some modulation of cerebral 
energy metabolism by serotonin was seemingly lost in that group of 
patients with schizophrenia, although the causality is hard to establish. 
Serotonin and dopamine innervations exhibit considerable overlap 
or convergence in the brain, notably in the basal ganglia, which raises 
the possibility of serotonergic modulation of dopamine release. Indeed, 
treatment with the mixed 5HT1A/2A agonist psilocybin (a psychedelic 
substance) provoked amphetamine-like 20 % displacement of striatal 
[11C]raclopride binding in a group of seven healthy volunteers [103]. 
The extent of depersonalization experienced by these individuals 
correlated with the magnitude of their dopamine release, suggesting a 
mechanism whereby serotonin/dopamine interactions could contribute 
to psychotic symptoms. This background motivated a range of PET 
studies of post-synaptic serotonin receptors in schizophrenia. At least 
seven types exist in the brain, among which the best known are the 
5HT1A and 5HT2A receptors. 
The first PET study of serotonin receptors in schizophrenia detected 
no differences in the cortical binding of the 5HT2A antagonist ligand 
[18F]setoperone in a group of 14 medication free or naïve patients 
compared with healthy controls [104]. There were similar negative re-
sults in a subsequent [18F]setoperone study comparing groups of ten 
patients and controls [105], and another study with 13 patients, of 
whom ten were native to antipsychotic medication [106]. One [18F] 
setoperone study in six never-medicated patients reported a 16 % 
reduction in the frontal cortex [107], and there is a report of lower [18F] 
altanserin binding in cerebral cortex of patients at risk for conversion, 
and low binding in caudate in the subset who did go on to develop 
schizophrenia [108]. Another study using [18F]altanserin showed no 
abnormality in the cortical 5HT2A binding in a group of 15 first episode, 
unmedicated patients, but did report a small increase in the caudate 
compared to the control group [109]. Upon expanding their sample to 
30 patients, that research group reported 15 % lower BPND in the frontal 
cortex, specifically among the males. Furthermore, this decrease corre-
lated with more severe positive symptoms [110]. However, they did not 
replicate in the larger sample their report of increased caudate binding, 
suggesting an earlier false positive finding. 
These generally negative PET findings stand in contrast to post 
mortem binding study reporting a 28 % elevation in the binding of [3H] 
ketanserin in frontal cortex membranes from (n = 29) never medicated 
patients, but no such difference in material from (n = 16) previously 
medicated patients [111]. The authors went on to measure the 
displacement of [3H]ketanserin by a concentration series with the se-
rotonin agonist DOI; their analysis indicated that samples from the un-
medicated patients had a higher proportion of their binding sites in a 
agonist-binding state, which was likewise confirmed by a GTP-shift 
binding assay. This result predicts an elevation of 5HT2A agonist bind-
ing in patients with schizophrenia, which might be testable in studies 
using new PET agonist ligands [112]. Alternately, the observations in 
brain membranes could predict enhanced hemodynamic response to 
5HT2A agonists in patients with schizophrenia, even if the availability of 
cortical receptors were unchanged or reduced, this in analogy to the 
fMRI/D2 receptor study with quinpirole challenge, cited above. 
The 5HT1A binding site is a somatodendritic autoreceptor expressed 
on serotonin neurons, but which is also abundantly present as a heter-
oceptor in hippocampus. Several ligands are available for PET in-
vestigations of 5HT1A sites, mainly finding use in studies of atypical 
antipsychotic medication occupancy, i.e. [113,114]. However, a [11C] 
WAY 100,635 PET investigation of 22 medication-free patients with 
schizophrenia or schizoaffective disorder did not show any evidence of 
any difference in 5HT1A binding compared to that in 18 healthy vol-
unteers, despite post mortem results indicating elevated binding in pre-
frontal cortex [115]. This negative results was preceded by studies 
showing 10–20 % higher [11C]WAY 100,635 binding in temporal cortex 
of a group of 14 unmedicated patients [116], whereas another study 
with this ligand showed a small increase confined to the amygdala of the 
mostly drug-native group of 11 patients [117]. 
7. Acetylcholine receptors 
There is sparse documentation of binding sites other than dopamine 
or serotonin receptors and transporters in the molecular imaging liter-
ature on schizophrenia. The nicotinic acetylcholine receptors (nAChR) 
have naturally drawn some attention, due to the self-medication hy-
pothesis arising from the high incidence of smoking in clinical pop-
ulations, although recent research questions the impact of smoking on 
cognition in schizophrenia [118]. A SPECT study investigated the 
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binding of the α4β2 nAChR ligand [123I]5-IA-85,380 in smokers with 
confirmed abstinence for one week, which is long enough to clear 
nicotine and its main metabolite. Comparison of (n = 11) patients with 
schizophrenia with a group of controls matched for tobacco consump-
tion showed 25 % lower binding in cortex and thalamus of the with-
drawn patients [119]. Since these binding sites are normally 
upregulated (and inactivated) by repeated nicotine exposure, that study 
suggested an abnormal responsiveness of the receptors among schizo-
phrenia patients. A pilot study using 2-[18F]FA, a ligand for the α4β2 
subtype of nAChRs showed 60 % reduced thalamic BPND for a group of 
(n = 5) patients with schizophrenia who were smokers, but this effect 
was attributed to simple competition from residual nicotine [120]. 
Another pilot PET study introducing the α7-nAChR ligand [18F]ASEM 
showed 10–20 % lower uptake (VT, the total distribution volume; ml 
g− 1) in hippocampus of (n = 6) patients with schizophrenia (of which 
one smoker) compared with a larger control group [121]. 
Unlike the nicotinic receptors, which are ligand gated ion channels, 
the muscarinic acetylcholine receptors (mAChRs) are metabotropic G- 
protein receptors. PET or SPECT ligands are available for several sub-
types among the five different mAChR families, but there have been 
relatively few molecular imaging investigations, other than occupancy 
studies focusing on atypical antipsychotic medications [95]. However, 
various observations link muscarinic transmission with certain schizo-
phrenia symptoms [122], and post mortem analysis has shown a 25 % 
reduction in the M1 muscarinic binding site [123], and deficient allo-
steric modulation of N-[3H]methylscopolamine binding in vitro [124]. 
Similarly, a SPECT study with [123I]IQNB revealed 20 % lower M1 re-
ceptor binding in cortex and a 33 % reduction in caudate nucleus of a 
group of 12 medication free patients [125]. Another [123I]IQNB study 
from the same group showed approximately 60 % receptor occupancy at 
M1 sites in patients treated with clozapine [126], but the cross sectional 
design could not distinguish simple occupancy from a down-regulation 
of the receptors due to treatment. A more recent [123I]IDEX SPECT 
study in 30 medication-free patients showed a relationship between 
lower M1 muscarinic binding in dorsolateral prefrontal cortex with 
negative symptomatology and impairments in verbal memory [127]. 
8. Glutamate receptors 
The glutamate receptors constitute a diverse family of ligand gated 
ion channels including the abundant NMDA receptors, and the metab-
otropic receptors, which are typical G-protein coupled receptors with 
seven transmembrane domains. There are relatively few molecular im-
aging studies of glutamate transmission in schizophrenia, despite the 
implicit importance of glutamatergic transmission in that disease. This is 
partially due to the historical lack of useful ligands for imaging the 
NMDA-type glutamate receptors, which has been something of a holy 
grail in rdaiopharmaceutical chemistry. Very recent preclinical reports 
introduced ligands for the NR2B subunit of the NMDA receptor [128], 
but the fitness of ligands proposed to target the open channel state of the 
NMDA receptor [129] is a matter of ongoing research [130]. Nonethe-
less, early SPECT studies with the NMDA receptor ligand [123I] 
CNS-1261 were a high water mark in schizophrenia research of gluta-
matergic markers. In one of the first molecular imaging investigations of 
NMDA receptors in living human brain, [123I]CNS-1261 revealed oc-
cupancy of NMDA sites by ketamine [131]. Administration of ketamine 
can acutely evoke some aspects of schizophrenia symptomatology in 
healthy individuals. Indeed, correlation analysis showed an association 
between the severities of negative symptom scores of the brief psychi-
atric rating scale with higher occupancy evoked by the same dose of 
ketamine in healthy volunteers [132]. In a SPECT study undertaken in 
schizophrenia patients who were under stable treatment with clozapine, 
the total distribution volume (VT) of [123I]CNS-1261 was globally 
reduced by one third relative to untreated patients and likewise healthy 
controls [133]. As noted above for the case of M1 muscarinic receptors, 
reduced NMDA availability could indicate simple competition of 
clozapine at the binding sites, a down-regulation due to treatment, or a 
specifically disease-related decline in the binding site availability. Using 
a semiquantitative binding index for [123I]CNS-1261, Pilowsky et al. 
found significantly reduced NMDA binding in the left hippocampus in 
drug-free patients with schizophrenia, and a less prominent reduction in 
those patients taking clozapine or typical antipsychotics at the time of 
scanning, whereas typical antipsychotic medication had no such effect 
on hippocampal binding [134]. Furthermore, her study showed a sig-
nificant inverse correlation between [123I]CNS-1261 binding and the 
severity of residual psychotic symptoms in those patients who were 
under treatment with typical antipsychotics. SPECT results in the 
medication-free subgroup of patients showed a significant positive cor-
relation between [123I]CNS-1261 binding in the middle inferior frontal 
cortex with the duration of illness duration. These results are generally 
in line with the NMDA receptor hypofunction hypothesis of schizo-
phrenia and suggest that atypical antipsychotic treatment may 
contribute to alterations in NMDA receptor availability. These pio-
neering SPECT findings with [123I]CNS-1261 call for renewed attention 
to the issue of NMDA receptor availability and their open channel state 
in the context of schizophrenia. 
Glutamate also acts as a neurotransmitter at the eight members of the 
G-protein linked metabotropic glutamate receptor (mGluR) family, 
some of which may modulate other neurochemical factors implicated in 
schizophrenia. For example, the mGluR2 subtype forms a functional 
complex with cortical 5HT2A receptors, and their activation interferes in 
the physiological and behavior effects of psychedelic drugs [135]. Pre-
clinical findings implicate mGluR2 in the nucleus accumbens in the 
regulation of methamphetamine-induced dopamine release [136], 
which might be relevant to the dopamine sensitization state of schizo-
phrenia. While subtype specificity has been hard to obtain, there are 
now promising tracers for mGluR1 [137], a lead compound for mGluR2 
[138], and the successful tracer [11C]ABP688 for mGluR5 imaging in 
human brain [139]. A study with this tracer showed 24 % lower [11C] 
ABP688 binding in a group of (n = 15) patients with schizophrenia 
relative to a control group closely matched for age and smoking status 
[140]. This was despite the lack of compelling post mortem findings for 
mGluRs in schizophrenia, e.g. [141], perhaps reflecting allosteric 
modulation of the receptors in living brain, or alternately the poor 
test-retest reproducibility characteristic of [11C]ABP688 PET. 
9. Other neuroreceptors and biomarkers 
Among the four known classes of receptors for opioid peptides, only 
the μ-subtype has been probed in PET studies with the selective agonist 
ligand [11C]carfentanyl or less selective antagonist ligands such as [11C] 
diprenorphine [142]. The only PET study of opioid receptors in 
schizophrenia showed 10 % reductions in [11C]carfentanyl binding in 
striatum and the “hedonic network” in a group of (n = 20) patients, who 
also showed a markedly increased inter-regional correlation of binding 
compared with the control group [143]. The authors interpreted their 
results in light of the anhedonia and other negative symptoms of 
schizophrenia. 
The tuberomammillary nucleus of the hypothalamus hosts a small 
population of histamine neurons, which innervate the forebrain. Of the 
four known types of histamine receptors, only the H1 type (the site of 
action of sedating antihistamines) is yet amenable for study by PET, 
using the antagonist ligand [11C]doxepin. The BPND of this ligand was 50 
% lower in the prefrontal and cingulate cortices, but was unaffected in 
the thalamus, in a group of (n = 10) haloperidol-treated patients with 
schizophrenia compared with controls [144]. While atypical antipsy-
chotic medications, especially those that cause weight gain, bind to H1 
sites, haloperidol is without great H1 affinity. However, it could be that 
prolonged antipsychotic treatment down-regulates these binding sites 
by some mechanism. 
There was recently a flurry of activity surrounding the hypothesis 
that neuroinflammation contributes to the pathology of schizophrenia. 
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Activated microglia and macrophages in brain express high levels of a 
marker known as TSPO in the mitochondrial membrane, which is 
detectable using a range of PET or SPECT tracers [145]. A meta-analysis 
of 12 TSPO PET studies using various tracers showed significantly higher 
signal in grey matter, which was of small effect size when calculated as 
BPND, but was not significant when calculated as VT [146]. This 
discrepancy may be due to uncertainties in the validity of TSPO-BPND 
estimates, i.e. the lack of a true non-binding reference region. On the 
other hand, a follow-up study suggested that neuroinflammation to 
TSPO PET (quantified as VT) may be a transient phenomenon in psy-
chosis, perhaps related especially with the acute phase [147]. Other 
multimodal molecular imaging studies link microgliosis to TSPO PET in 
schizophrenia patients with attenuated extrastriatal dopamine release 
provoked by psychosocial stress [148], and to high levels of the inhib-
itory neurotransmitter GABA in frontal cortex, as measured by MR 
spectroscopy [149]. A further confounding factor in these studies is due 
to the bivalent nature of microglia, which can have pro-inflammatory or 
anti-inflammatory phenotypes. Application of tracers that target other 
specific aspects of neuroinflammation pathways may help resolve this 
issue [150]. 
Results of multimodal TSPO-PET/MR spectroscopy studies introduce 
the topic of molecular imaging of the nearly ubiquitous GABA-A binding 
sites with the benzodiazepine [11C]flumazenil. Since GABA-A sites are 
so very abundant in the cerebral cortex, [11C]flumazenil PET gives a 
surrogate index of neuronal density and cortical thickness in healthy 
brain [151]. Baseline [11C] flumazenil VT did not differ in groups of 
healthy controls and unmedicated patients with schizophrenia, which 
might indicate preservation of cortical architecture in schizophrenia 
[152]. However, group differences emerged upon pharmacological 
challenge with tiagabine, a blocker of the GABA plasma membrane 
transporter. This treatment normally elevates interstitial GABA levels, 
which increases the affinity of GABA-A sites for [11C]flumazenil by an 
allosteric mechanism. Indeed, the tiagabine treatment provoked a 10–15 
% increase in the [11C]flumazenil VT in the healthy control group, but no 
significant effect in the antipsychotic naïve patients. The authors pro-
posed that this difference revealed an underlying defect in GABA-ergic 
signaling in schizophrenia. Another [11C]flumazenil PET study showed 
20 % lower VT specifically in the right caudate of a group of individuals 
at extreme risk for developing psychosis [153], which had not been 
reported in the preceding study of patients with schizophrenia. 
Post mortem investigation showed reduced protein levels of the 
metabotropic GABA-B receptors in patients with schizophrenia, but 
there were similar reductions in samples from other psychiatric pop-
ulations [154]. There is a PET ligand for GABA-B sites validated for 
rodent studies [155], but at the time of writing, there are no molecular 
imaging studies of this target in schizophrenia patients. 
Broadly speaking, the preponderance of neurotransmission is either 
inhibitory (GABA-ergic) or excitatory (glutamatergic), with additional 
modulation or shaping by biogenic monoamine and peptide neuro-
transmitters. A recent proposal integrates the original dopamine hy-
pothesis of schizophrenia in a model positing disturbances in a triad of 
neurochemical networks: dopamine, serotonin, and glutamate [156]. In 
this scenario, abnormal glutamate-serotonin interactions in (frontal) 
cerebral cortex propagate to dysregulation of mesolimbic dopamine 
transmission. As noted above, patients, but not healthy controls, showed 
a very tight coupling between attenuated activation of BOLD signal in 
frontal cortex while performing a cognitive task, and elevated FDOPA 
uptake in the striatum [29]. Meta-analysis of many MR spectroscopy 
studies of glutamate/glutamine in schizophrenia indicates elevations in 
several brain regions [157]; we suppose that excessive excitatory 
transmission in frontal cortex may block the performance of certain 
cognitive tasks. A recent multimodal study investigated the relationship 
between cortical glutamate signals measured by MR spectroscopy with 
subcortical dopamine synthesis capacity to FDOPA PET in (n = 28) 
patients with schizophrenia [158]. In that study, the glutamate level in 
prefrontal cortex correlated inversely with FDOPA uptake in ventral 
striatum, whereas there was a positive association with striatal gluta-
mate levels. A completely independent multimodal imaging study of 
similar design substantially replicated the finding of an inverse associ-
ation between cortical glutamate and subcortical dopamine [159], 
which furthermore showed a very strong correlation between positive 
symptom scores and cortical glutamate. Interestingly, others have re-
ported that the stimulation of striatal perfusion to 15O-water PET by 
treatment with antipsychotic medication correlated with baseline 
FDOPA utilization in striatum correlated with clinical improvement 
[160]. This could imply that a glutamate-mediated hyper-responsive 
perfusion increase in striatum predicts for a hyperactive dopamine 
system that could be amenable to treatment. 
Ligands are now available for the molecular imaging of the synaptic 
vesicle protein 2A (SV2A), which provide an index of overall synaptic 
density. For example, [11C]UCB-J sensitively detected a 40 % reduction 
in SV2A binding in patients with Alzheimer’s disease [161]. In a group 
of (n = 18) patients with schizophrenia, [11C]UCB-J PET revealed 
significantly lower binding of large effect size in frontal and anterior 
cingulate cortices, but no difference in hippocampus compared with the 
healthy control group [162]. The reductions were about 15 %, sug-
gesting of widespread synaptic loss in those regions, although not to the 
same extent as in the frank neurodegeneration of Alzheimer’s disease. 
We can predict that declines in cortical SV2A binding in schizophrenia 
should track the pattern of hypermetabolism seen in FDG PET. 
Histone acetylase enzymes remove the acetyl group from histone 
proteins on DNA, thus interfering with the access of transcription factors 
and mediating epigenetic effects. A recent PET study with the non- 
selective histone acetylase ligand [11C]martinostat indicated 50 % 
lower binding specifically confined to the dorsolateral prefrontal cortex 
of a mixed group of schizophrenia/schizoaffective patients [163]. There 
was a more widespread reduction in [11C]martinostat binding in brain of 
patients with bipolar disorder, involving the thalamus, amygdala and 
hippocampus [164]. Thus, the focal finding in dorsolateral prefrontal 
cortex of schizophrenia might relate to working memory and executive 
function deficits of that condition. Here, the PET result of reduced his-
tone acetylase binding overlaps with findings reported above for dopa-
mine D1 receptors and M1 muscarinic receptors. 
10. Conclusion 
Molecular imaging by PET or SPECT enables the non-invasive mea-
surement of cerebral biomarkers across the spectrum extending from 
prodromal or UHR states preceding schizophrenia, to an acute phase, 
later remission from psychosis, and long-term outcome. In addition, test- 
retest molecular imaging studies allow dynamic assessments of re-
sponses to medications or psychosocial challenges. In contrast, post 
mortem examinations of brain usually reveal the end stage of a chronic 
illness, and bear the mark of perhaps decades of various treatment. 
Avoiding confounds due to treatment is logistically difficult in molecular 
imaging studies in schizophrenia, but may be the only way to separate 
trait, state, and medication effects. More than a generation of research in 
molecular imaging has failed to discover any marker that is pathogno-
monic of schizophrenia. While reduced blood flow and glucose meta-
bolism in frontal brain regions are frequent findings, this kind of result is 
by no means diagnostic. Likewise, PET shows elevated capacity for 
dopamine synthesis in striatum in about half of cases, whereas D2/3 
receptor SPECT studies show elevated receptor occupancy at baseline 
and greater occupancy increases in response to amphetamine challenge, 
also in about half of cases. Presumably, the 50 % of schizophrenia pa-
tients with high dopamine synthesis are the same individuals who show 
greater responses to amphetamine challenge at post-synaptic receptors, 
and may be apt to have a better response (in positive symptoms) to 
antipsychotic medication. Furthermore, multimodal imaging studies 
suggest a link between elevated cortical glutamate and subcortical 
dopamine abnormalities. However, various lines of evidence indicate 
higher variance in dopaminergic measures among patients than in 
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control groups, which is itself suggestive of biochemical heterogeneity. 
When dopamine is not to blame, what is? 
There are inconsistent findings of reduced serotonin 5HT2A receptor 
availability in frontal cortex, which could hypothetically link impaired 
glutamatergic transmission in cortex and subcortical dopaminergic in-
creases, as in the triad model recently proposed by Stahl [156]. In-
vestigations of a wide range of other molecular imaging targets, usually 
in studies of small sample size, have shown either no differences, or 
small-moderate reductions in patients, i.e. cortical dopamine D1, 
μ-opioid, histamine H1, nicotinic, GABA-A, and mGluR5 receptors. In the 
absence of any particular hypothesis, PET researchers are seemingly 
seeking a highly sensitive neurochemical marker for schizophrenia by a 
process of elimination. In summary, four decades of molecular imaging 
studies of schizophrenia suggest a broad pathology affecting various 
neuotransmitter systems with overall loss of function, with the exception 
of a local over-activity of dopamine in striatum, and possibly in frontal 
cortex. Alternately, the brain of patients with schizophrenia may bear 
the marks of a decade of neurochemical aging in excess of chronological 
age, as shown by the small but significant declines reported for various 
other receptor types. Recent findings of reduced synaptic density rein-
force this impression. Furthermore, inter-regional correlational analysis 
of PET results is widely used to tease out abnormal metabolic or neu-
roreceptor coupling, as distinct from absolute, statistically significant 
changes in receptor density, enzyme activity, or some other physiolog-
ical parameter. What we call schizophrenia may remain a miasma of 
diffuse neurochemical changes more indicative of a generally ailing and 
functionally disconnected brain than of a singular disease pathology. 
However, this somewhat pessimistic view may yet yield to studies with 
new classes of receptor ligands. 
A central aspect of the problem at hand is the unfitness of typical 
PET/SPECT studies in groups of perhaps 20 subjects to accommodate the 
high variability of endpoints, which may be due to disease heteroge-
neity, staging, and carryover of previous treatment effects. Although 
meta-analyses have been very successful in establishing the extent of 
changes in dopaminergic markers, we suppose that prospective multi-
center studies may be required to obtain sufficient statistical power to 
parse out neurochemical subtypes of schizophrenia. In addition, a 
multimodal imaging approach may help to depict better the complexity 
of schizophrenia, as suggested by Stahl [156]. For example, a study 
combining structural and functional MR imaging with dual molecular 
imaging of dopamine synthesis capacity and glutamate receptors might 
support conclusions about heterogeneity of neurochemical and func-
tional aspects of schizophrenia. Here, machine-learning techniques may 
reveal hidden aspects of the data, as demonstrated for the case of FDOPA 
[45]. This data-driven approach may help to simplify and resolve the 
hard trade-off between physiological resolution versus the logistics and 
costs of complex studies in large patient populations. 
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